Rapid Micro Biosystems (RPID) 44th Annual J.P. Morgan Healthcare Conference summary

Business Overview and Market Context

• Automates microbial quality control for pharmaceutical manufacturing, replacing manual Petri dish methods with the Growth Direct Platform.

• Operates in about 20 countries, serving 75% of the top 20 pharma companies and excelling in biologics and cell/gene therapy.

• Achieved $34 million in 2025 revenue with 20% growth and $18 million in recurring revenue, with recurring revenue forming over half of total revenue.

• 190 Growth Direct systems placed globally, with 155 validated for routine use and presence at over 100 customer manufacturing sites.

• Strengthened balance sheet with a $45 million debt facility and $38 million cash at year-end, aiming for break-even without further financing.

Technology and Value Proposition

• Growth Direct Platform automates high-volume microbial testing, improving data integrity and operational efficiency.

• Provides results in half the time or less compared to manual methods, reducing errors and labor costs.

• Integrates with customer information systems for secure data exchange.

• Only fully automated, high-throughput MQC solution, adopted by 86% of approved CAR-T manufacturers.

• Applications include environmental monitoring, water testing, bioburden, and rapid sterility testing.

Growth Strategy and Customer Expansion

• Employs a land-and-expand strategy: initial system placement followed by network-wide expansion and application onboarding.

• Focus on new product launches, expanding upstream/downstream offerings, and targeting adjacent markets like food, personal care, and medical devices.

• Partnership with MilliporeSigma aims to accelerate growth, margin expansion, and access to new markets, with significant impact expected in 2026.

• Not fully penetrated in current customer base, with significant runway for additional systems and services.

• Commercial momentum supported by multi-system orders and expanding recurring revenue from consumables and services.